At #ESMO24, the focus wasn’t just on the here and now—but the future of oncology. From honing in on the next generation of IO therapies and leveraging technology to bring us to a new era of precision medicine - the discussions pointed to where cancer care is headed. Plenty to reflect on and share with our pharma partners. Check out our key takeaways below.
Siobhan Davies and Lindsay Widger bring you the key insights you won’t want to miss from this year's ESMO - European Society for Medical Oncology Congress. Including... ↪ Neoadjuvant IO in dMMR Colon Cancer: is the NICHE-2 trial enough to change the standard of care? ❓ IO in Solid Tumors: what’s next on the horizon after anti-PD-(L)1 therapies? 😕 Adjuvant Therapy and MRD: how do patients weigh up their options when the next steps aren’t always clear? 📃 Please take a look at our short summary. We hope you will find it informative and thought provoking. 📩 Contact us oncology@beyondblueinsight.com to set up a walk and talk through for you and your team!
